Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML

被引：7
|
作者：
Sorel, Nathalie
Roy, Lydia
Martineau, Geraldine
Guilhot, Francois
Turhan, Ali G.
Chomel, Jean-Claude
机构：
[1] CHU Poitiers, Lab Hematol, F-86021 Poitiers, France
[2] CHU Poitiers, EA 3805, F-86021 Poitiers, France
来源：
BLOOD | 2006年 / 108卷 / 05期
关键词：
D O I：
10.1182/blood-2006-03-011668
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1782 / 1783
页数：2
相关论文
共 50 条
  • [41] Sequential kinase inhibitor therapy in CML patients can select for cells harboring compound BCR-ABL kinase domain mutations with increased oncogenic potency: Rationale for early combination therapy of ABL kinase inhibitors.
    Shah, Neil P.
    Skaggs, Brian
    Branford, Susan
    Hughes, Timothy P.
    Nicoll, John M.
    Paquette, Ronald L.
    Sawyers, Charles L.
    BLOOD, 2006, 108 (11) : 225A - 226A
  • [42] BCR-ABL TYROSINE KINASE MUTATIONS IN IMATINIB MESYLATE RESISTANT CML PATIENTS FROM OMAN: SINGLE CENTRE EXPERIENCE
    Pathare, V.
    Alkindi, S.
    Al Zadjali, A.
    Al Farsi, S.
    Huneini, N.
    Zia, B.
    Dennison, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 576 - 576
  • [43] Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression
    Tang, Carine
    Schafranek, Lisa
    Watkins, Dale
    Parker, Wendy T.
    Prime, Jodi
    White, Deborah L.
    Hughes, Timothy
    BLOOD, 2010, 116 (21) : 1385 - 1385
  • [44] A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells
    Saunders, Verity A.
    Wang, Jueqiong
    Lu, Liu
    Eadie, Laura N.
    McLean, Jennifer A.
    Goyne, Jarrad M.
    Yeung, David T.
    White, Deborah L.
    Hughes, Timothy P.
    BLOOD, 2016, 128 (22)
  • [45] Next-Generation Medicine: Combining BCR-ABL and Hedgehog-Targeted Therapies
    Dao, Kim-Hien T.
    Tyner, Jeffrey W.
    CLINICAL CANCER RESEARCH, 2013, 19 (06) : 1309 - 1311
  • [46] Comparison of Different Laboratory Methods for Quantification of BCR-ABL Kinase Domain Mutations In CML Patients Undergoing Tyrosine Kinase Inhibitor Therapy
    Press, Richard D.
    Yang, Fei
    BLOOD, 2010, 116 (21) : 1138 - 1138
  • [47] THE RATE OF BCR-ABL KINASE DOMAIN MUTATIONS IN CML PATIENTS RESISTANT TO TYROSINE KINASE INHIBITOR TREATMENT IN SOUTH AFRICA, UNUSUAL FINDINGS
    Schnugh, D.
    Pascale, W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 529 - 530
  • [48] PREVALENCE OF BCR-ABL IMATINIB RESISTANT MUTATIONS IN PORTUGUESE CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS
    Palmeiro, A.
    Torres, F.
    Lemos, R.
    Teixeira, M.
    Gabriel, H.
    Rendeiro, P.
    Tavares, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 539 - 539
  • [49] Targeted detection of BCR-ABL kinase domain mutations using FlexMap microspheres and Luminex Bead array technology
    Frederick, L. A.
    McClure, R. F.
    Viswanatha, D.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2007, 9 (05): : 668 - 668
  • [50] Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
    Cortes, Jorge
    Jabbour, Elias
    Kantarjian, Hagop
    Yin, C. Cameron
    Shan, Jianqin
    O'Brien, Susan
    Garcia-Manero, Guillermo
    Giles, Francis
    Breeden, Megan
    Reeves, Nubia
    Wierda, William G.
    Jones, Dan
    BLOOD, 2007, 110 (12) : 4005 - 4011
12345